Evidence map›Paper›PMID 38395539›Full record

Trial reportThe Lancet. Digital health2024

Optimal strategies to improve uptake of and adherence to HIV prevention among young people at risk for HIV acquisition in the USA (ATN 149): a randomised, controlled, factorial trial.

Dallas Swendeman, Mary Jane Rotheram-Borus, Elizabeth Mayfield Arnold, Maria Isabel Fernández, Walter Scott Comulada, Sung-Jae Lee, Manuel A Ocasio, Kelsey Ishimoto, William Gertsch, Naihua Duan and 4 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Lancet. Digital health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03134833 (Engaging Seronegative Youth to Optimize HIV Prevention Continuum), which is not on this map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03134833 nacompletednot on this map

Engaging Seronegative Youth to Optimize HIV Prevention Continuum

TypeinterventionalSponsorUniversity of California, Los AngelesRan2017 to 2022Enrolled1,478ConditionsHIV, Mental Health, Substance Use, STIArmsAutomated Messaging & Monitoring, Peer Support, Coaching
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Utilizing Machine Learning for Predicting PrEP Use Status Among Sexual and Gender Minority Young Adults.Prevention science : the official journal of the Society for Prevention Research · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Dallas SwendemanSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA. Electronic address: dswendeman@mednet.ucla.edu.
Mary Jane Rotheram-BorusSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Elizabeth Mayfield ArnoldDepartment of Psychiatry, College of Medicine, University of Kentucky, Lexington, KY, USA.
Maria Isabel FernándezCollege of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.
Walter Scott ComuladaSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Sung-Jae LeeSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Manuel A OcasioDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA.
Kelsey IshimotoSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
William GertschSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Naihua DuanDivision of Mental Health Data Science, Department of Psychiatry, Columbia University, New York, NY, USA.
Cathy J RebackFriends Research Institute, Los Angeles, CA, USA.
Debra A MurphySemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Katherine A LewisSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Adolescent HIV Medicine Trials Network (ATN) CARES Study Team
University of California, Los Angeles · USColumbia University · USFriends Research Institute · USNova Southeastern University · USTulane University · USUniversity of Kentucky · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
Optimizing the HIV Treatment Continuum with a Stepped Care Model for Youth Living with HIVU19HD089886 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FERNANDEZ, MARIA ISABEL, ROTHERAM-BORUS, MARY JANE · 2016 to 2022
$23.4M
NCATS NIH HHS UL1 TR001881NIAID NIH HHS P30 AI028697NICHD NIH HHS U19 HD089886NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

backgroundPre-exposure prophylaxis (PrEP), condom use, post-exposure prophylaxis (PEP), and sexual partner reduction help to prevent HIV acquisition but have low uptake among young people. We aimed to assess the efficacy of automated text messaging and monitoring, online peer support, and strengths-based telehealth coaching to improve uptake of and adherence to PrEP, condom use, and PEP among adolescents aged 12-24 years at risk of HIV acquisition in Los Angeles, CA, USA, and New Orleans, LA, USA.

methodsWe conducted a four-arm randomised controlled factorial trial, assessing interventions designed to support uptake and adherence of HIV prevention options (ie, PrEP, PEP, condom use, and sexual partner reduction). We recruited young people aged 12-24 years who were at risk of HIV acquisition from 13 community-based organisations, adolescent medicine clinics, and organisations serving people who are unstably housed, people who were previously incarcerated, and other vulnerable young people, and through dating apps, peer referrals, and social venues and events in Los Angeles, CA, USA, and New Orleans, LA, USA. Young people who tested seronegative and reported being gay, bisexual, or other men who have sex with men, transgender men or women, or gender diverse (eg. non-binary or genderqueer) were eligible for inclusion. Participants were randomly assigned to one of four intervention groups in a factorial design: automated text messaging and monitoring (AMMI) only, AMMI plus peer support via private social media, AMMI plus strengths-based telehealth coaching by near-peer paraprofessionals, or AMMI plus peer support and coaching. Assignment was further stratified by race or ethnicity and sexual orientation within each interviewer's group of participants. Participants were masked to intervention assignment until after baseline interviews when offered their randomly assigned intervention, and interviewers were masked throughout the study. Interventions were available throughout the 24-month follow-up period, and participants completed baseline and follow-up assessments, including rapid diagnostic tests for sexually transmitted infections, HIV, and substance use, at 4-month intervals over 24 months. The primary outcomes were uptake and adherence to HIV prevention options over 24 months, measured by self-reported PrEP use and adherence, consistent condom use with all partners, PEP prescription and adherence, and number of sexual partners in participants with at least one follow-up. We used Bayesian generalised linear modelling to assess changes in outcomes over time comparing the four study groups. This study is registered with ClinicalTrials.gov (NCT03134833) and is completed.

findingsWe screened 2314 adolescents beginning May 1, 2017, to enrol 1037 participants (45%) aged 16-24 years between May 6, 2017, and Aug 30, 2019, of whom 895 (86%) had follow-up assessments and were included in the analytical sample (313 assigned to AMMI only, 205 assigned to AMMI plus peer support, 196 assigned to AMMI plus coaching, and 181 assigned to AMMI plus peer support and coaching). Follow-up was completed on Nov 8, 2021. Participants were diverse in race and ethnicity (362 [40%] Black or African American, 257 [29%] Latinx or Hispanic, 184 [21%] White, and 53 [6%] Asian or Pacific Islander) and other sociodemographic factors. At baseline, 591 (66%) participants reported anal sex without a condom in the past 12 months. PrEP use matched that in young people nationally, with 101 (11%) participants reporting current PrEP use at baseline, increasing at 4 months to 132 (15%) and continuing to increase in the AMMI plus peer support and coaching group (odds ratio 2·31, 95% CI 1·28-4·14 vs AMMI control). There was no evidence for intervention effect on condom use, PEP use (ie, prescription or adherence), PrEP adherence, or sexual partner numbers. No unanticipated or study-related adverse events occurred.

interpretationResults are consistent with hypothesised synergistic intervention effects of evidence-based functions of informational, motivational, and reminder messaging; peer support for HIV prevention; and strengths-based, goal-focused, and problem-solving telehealth coaching delivered by near-peer paraprofessionals. These core functions could be flexibly scaled via combinations of technology platforms and front-line or telehealth HIV prevention workers.

fundingAdolescent Medicine Trials Network for HIV/AIDS Interventions, US National Institutes of Health.

Indexed as

Acquired Immunodeficiency SyndromeHIV InfectionsSexual and Gender MinoritiesAdolescentBayes TheoremFemaleHomosexuality, MaleHumansMaleUnited States

Identifiers

PMID38395539
PMCPMC11371121
OpenAlexW4391989667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.